TY - JOUR
T1 - Multi-color CD34 + progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia
AU - Tang, Guilin
AU - Jorgensen, Jeffrey L.
AU - Zhou, Yi
AU - Hu, Ying
AU - Kersh, Marian
AU - Garcia-Manero, Guillermo
AU - Jeffrey Medeiros, L.
AU - Wang, Sa A.
PY - 2012/8
Y1 - 2012/8
N2 - Bone marrow assessment for myelodysplastic syndrome (MDS) in a patient who develops cytopenia(s) following cancer therapy is challenging. With recent advances in multi-color flow cytometry immunophenotypic analysis, a CD34 + progenitor-focused 7-color assay was developed and tested in this clinical setting. This assay was first performed in 73 MDS patients and 53 non-MDS patients (developmental set). A number of immunophenotypic changes were differentially observed in these two groups. Based on the sensitivity, specificity and reproducibility, a core panel of markers was selected for final assessment that included increased total CD34 + myeloblasts; decreased stage I hematogones; altered CD45/side scatter; altered expression of CD13, CD33, CD34, CD38, CD117, and CD123; aberrant expression of lymphoid or mature myelomonocytic antigens on CD34 + myeloblasts; and several marked alterations in maturing myelomonocytic cells. The data were translated into a simplified scoring system which was then used in 120 patients with cytopenia(s) secondary to cancer therapy over a 2-year period (validation set). With a median follow-up of 11 months, this assay demonstrated 89% sensitivity, 94% specificity, and 92% accuracy in establishing or excluding a diagnosis of MDS.
AB - Bone marrow assessment for myelodysplastic syndrome (MDS) in a patient who develops cytopenia(s) following cancer therapy is challenging. With recent advances in multi-color flow cytometry immunophenotypic analysis, a CD34 + progenitor-focused 7-color assay was developed and tested in this clinical setting. This assay was first performed in 73 MDS patients and 53 non-MDS patients (developmental set). A number of immunophenotypic changes were differentially observed in these two groups. Based on the sensitivity, specificity and reproducibility, a core panel of markers was selected for final assessment that included increased total CD34 + myeloblasts; decreased stage I hematogones; altered CD45/side scatter; altered expression of CD13, CD33, CD34, CD38, CD117, and CD123; aberrant expression of lymphoid or mature myelomonocytic antigens on CD34 + myeloblasts; and several marked alterations in maturing myelomonocytic cells. The data were translated into a simplified scoring system which was then used in 120 patients with cytopenia(s) secondary to cancer therapy over a 2-year period (validation set). With a median follow-up of 11 months, this assay demonstrated 89% sensitivity, 94% specificity, and 92% accuracy in establishing or excluding a diagnosis of MDS.
KW - CD34 progenitors
KW - Cytopenia
KW - Multi-color flow cytometry
KW - Myelodysplastic syndromes
KW - Myelomonocytic cells
KW - Therapy-related
UR - http://www.scopus.com/inward/record.url?scp=84862578497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862578497&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2012.05.001
DO - 10.1016/j.leukres.2012.05.001
M3 - Article
C2 - 22626984
AN - SCOPUS:84862578497
SN - 0145-2126
VL - 36
SP - 974
EP - 981
JO - Leukemia Research
JF - Leukemia Research
IS - 8
ER -